To view this email as a web page, click here.

 
Dermatology Times
Warning signs of life-threatening purpura
Do you know the warning signs of life threatening purpura? Dr. Roderick Hay outlines what you need to know about potentially life-threatening conditions involving purpura.
ADVERTISEMENT
 
Arriving at a skin hemorrhaging diagnosis
Clinicians are more likely to correctly identify the lesions' underlying cause with careful observation rather than with several lab tests.
 
Top 3 biosimilar developments of 2018
The biosimilars market is expected to exceed $10.9 billion by 2021, but the commercialization of biosimilars have lagged. Expert Mark Ginestro offers his insights on the top 3 biosimilar developments on 2018 and what they may mean for adoption in the coming year.
 
From our Latest Issue
 
Dermatology Times cover
AAD updates cutaneous melanoma guidelines
 
Artificial Intelligence. Friend or foe of dermatology?
 
Medicare physician fee schedule changes
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
The Cosmetic Professional’s Guide to Patient Financing
Would you like to grow your revenue while saving thousands in provider fees? Download the Ultimate Guide to Patient Financing to learn how! Read more.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.